期刊文献+

阿哌沙班的合成新工艺 被引量:7

New synthetic process of apixaban
原文传递
导出
摘要 目的:对目前阿哌沙班的合成路线进行优化,以获得适合工业化生产的工艺路线。方法:以硝基化合物6为原料,依次经铁粉还原-酰胺化、环合-水解反应得阿哌沙班酸2;2与廉价绿色试剂CDI反应所得活性酰胺经氨水氨解得目标化合物阿哌沙班。结果:所得阿哌沙班经HPLC检测纯度为99.88%以上,总收率为67.2%。结论:此方法克服了文献报道的方法中原料价格昂贵,反应条件苛刻,反应过程不易监测,产品收率低等缺点。具有原料易得、生成成本低,反应条件温和、操作简便,工艺稳定性高,阿哌沙班纯度和收率高等优点,适合工业化生产。 Objective: To develop a new synthetic route for apixaban by optimizing the reported synthesis routes. Methods: Nitro-compound 6 was used as starting material and it was subjected to the reactions of iron reduction, acylation, cyclization and hydrolysis to generate apixaban acid 2. Apixaban acid 2 was reacted with CDI to afford an active amide, followed by aminolysis with aqueous ammonia to produce the target compound apixaban. Results: Apixaban was synthesized with a total yield of 67.2% , and the purity was 〉 99.88% as determined by HPLC. Conclusion : This route has overcome the shortcomings of the reported synthesis methods for apixaban, such as the expensive materials, harsh and not easy to be monitored reaction conditions, low yield, et al. In this paper, a significantly improved strategy has been developed to meet the requirement for industrial production, with the ad- vantages of low production cost, simple operation, mild reaction conditions, high process stability, and high purity of the target product, et al
出处 《中国新药杂志》 CAS CSCD 北大核心 2015年第11期1290-1294,共5页 Chinese Journal of New Drugs
关键词 阿哌沙班 阿哌沙班酸 1 1’-羰基二咪唑(CDI) 合成 apixaban apixaban acid 1, l'-carbonyldiimidazole(CDI) synthesis
  • 相关文献

参考文献15

  • 1田国祥,魏万林,张灵.后华法林时代口服抗凝新秀:达比加群、利伐沙班、阿哌沙班[J].中国循证心血管医学杂志,2011,3(5):403-406. 被引量:23
  • 2WONG PC, JIANG X. Apixaban, a direct factor Xa inhibitor, inhibits tissue-factorinduced human platelet aggregation in vitro: comparison with direct inhibitors of factor VIIa, XIa, and throm- bin[J]. Thromb Haemost,2010, 104(2) : 302 -310.
  • 3任玉杰,杜成,刘世梦.新型抗凝血药合成及应用研究[J].上海应用技术学院学报(自然科学版),2012,12(4):274-281. 被引量:5
  • 4钱方毅.新型口服抗凝剂临床应用的进展[J].中国循环杂志,2012,27(4):246-250. 被引量:8
  • 5GANT TG, SHAHBAZ M. Pyrazole carboxamide inhibitors of factor Xa: WO, 2010030983A2 [ P ]. 2010 - 03 - 18.
  • 6薛吉军,李毅,王仕祥,等.一种抗血栓药物阿哌沙班的制备方法:中国,103342704A[P].2013—10—09.
  • 7赵纪山,徐强,徐卓业,等.一种阿哌沙班的合成方法:中国,102675314A[P].2012-09-19.
  • 8SHAPIRO R, ROSSANO, LT, MUDRYK BM, et al. Process for preparing 4, 5-dihydro-pyrazolo [ 3, 4-C ] pyrid-2-ones: US, 20060069258A1 [ P]. 2006 -03 - 30.
  • 9尚振华,王江霞.一种阿哌沙班的制备方法:中国,104045637A[P].2014-09-17.
  • 10邢峻豪,张媛,胡晓雯,周金培,张惠斌.阿哌沙班衍生物的合成及Ⅹa因子抑制活性[J].中国药科大学学报,2013,44(4):289-295. 被引量:4

二级参考文献89

  • 1张治云,凌沛学,王凤山,张天民.低分子肝素药理作用研究进展[J].食品与药品,2006,8(01A):7-9. 被引量:24
  • 2国家"十五"攻关"肺栓塞规范化诊治方法的研究"课题组,杨媛华,翟振国,武燕兵,王辰.急性肺血栓栓塞症患者516例临床表现分析[J].中华医学杂志,2006,86(31):2161-2165. 被引量:78
  • 3冀亚飞,蒋健安,刘倩,等.一种抗血栓药物阿匹沙班的制备方法:中国,101967145[P].2010-09-09.
  • 4Friedman RJ,Dahl OE,Rosencher N,et al.Dabigatran versus enoxaparin for prevention of venous thromboembolism after hip or knee arthroplasty:a pooled analysis of three trials[J].Thromb Res,2010,126(3):175-182.
  • 5Eriksson BI,Dahl OE,Huo MH,et al.Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II*)[J].Thromb Haemost,2011,105(4):721-729.
  • 6Schulman S,Kearon C,Kakkar AK,et al.Dabigatran versus warfarin in the treatment of acute venous thromboembolism[J].N Engl J Med,2009,361(24):2342-2352.
  • 7Connolly SJ,Ezekowitz MD,Yusuf S,et al.Dabigatran versus warfarin in patients with atrial fibrillation[J].N Engl J Med,2009,361(12):1139-1151.
  • 8Wann LS,Curtis AB,Ellenbogen KA,et al.2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (update on Dabigatran):a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines[J].Circulation,2011,123(10):1144-1150.
  • 9Oldgren J,Budaj A,Granger CB,et al.Dabigatran vs.placebo in patients with acute coronary syndromes on dual antiplatelet therapy:a randomized,double-blind,phase II trial[J].Eur Heart J,2011,32(22):2781-2789.
  • 10Eriksson BI,Borris LC,Friedman RJ,et al.Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty[J].N Engl J Med,2008,358(26):2765-2775.

共引文献38

同被引文献38

  • 1冀亚飞, 江健安, 刘倩, 等. 一种抗血栓药物阿匹沙班的制备方法: 中国, 201010277358.0[P]. 2011-02-09.
  • 2薛吉军,李毅,王仕祥,等.一种抗血栓药物阿哌沙班的制备方法:中国,103342704A[P].2013—10—09.
  • 3赵纪山,徐强,徐卓业,等.一种阿哌沙班的合成方法:中国,102675314A[P].2012-09-19.
  • 4叶天健,刘涛,马苏旺.4-环内酰胺基苯胺的制备方法:中国,103709095A[P].2014-04-09.
  • 5Hohnloser SH, Hijazi Z, Thomas L, et al. Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial [J]. Eur Heart J, 2012, 33 (22): 2821-- 2830.
  • 6Gant TG, Shahbaz M. Pyrazole carboxamide inhibitors of factor Xa: WO, 2010030983A2 [P]. 2010-03-18.
  • 7Zhou JC, Oh LM, Ma P, et al. pyrazolo 3,4-c pyrid-2-ones 2003-06-19. Synthesis of 4,5-dihydro- WO, 03049681A2 [P].
  • 8叶大健,刘涛,马苏旺.4一环内酰胺基苯胺的制备方法:中国,103709095A[P].2014-04-09.
  • 9Shapiro R, Rossano LT, Mudryk BM, et al. Process for preparing 4,5-dihydro-pyrazolo E 3,4-c pyrid-2-ones: US, 20060069258A1 [P]. 2006-03-30.
  • 10Jian' an Jiang, Yafei Ji. Alternate synthesis of Apixaban(BMS-562247), An inhibitor of blood coagulation factor Xa[J]. Synthetic Communications, 2013, 43: 72-79.

引证文献7

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部